PDX1 and cancer: The first study was performed by Tuveson’s group using a PDAC-PSC organoid system as well as in genetically engineered mouse model, KPC mice (KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-1-Cre), and revealed the presence of two distinct CAF subtypes [4]: a subpopulation of CAFs near cancer cells expressing high levels of αSMA and named myofibroblast-like CAFs (myCAFs), and a subpopulation of CAFs distant form cancer cells with a high secretory expression profile named inflammatory CAFs (iCAFs).